Pharmacology of purine nucleoside analogues

Hematology and Cell Therapy

Volumn 38, Issue SUPPL. 2, 1996, Pages

  Plunkett, W ^a   Gandhi, V ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

cladribine; fludarabine; nucleotide analogues; pentostatin

Indexed keywords

CLADRIBINE; FLUDARABINE; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE;

HUMAN; LEUKEMIA; LYMPHOMA; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLADRIBINE; HEMATOLOGIC NEOPLASMS; HUMANS; PENTOSTATIN; PURINE NUCLEOSIDES; VIDARABINE;

EID: 0029850884     PISSN: 14302772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Agarwal RP (1982) Inhibitors of adenosine deaminase. Pharmac Ther 17 : 399-429
2. Agarwal RP, Parks RE Jr (1977) Potent inhibition of muscle 5′-AMP deaminase by the nucleoside antibiotics coformycin and deoxycoformycin. Biochem Pharmacol 26 : 663-666
3. Agarwal RP, Spector T, Parks RE Jr (1977) Tight-binding inhibitors IV. inhibition of adenosine deaminase by various inhibitors. Biochem Pharmacol 26 : 359-367
4. Albertioni F, Pettersson B, Reichelova V, et al (1995) Analysis of 2-chloro-2′-deoxyadenosine in human blood samples and urine by high-performance liquid chromatography using solid-phase extraction. Ther Drug Monit 61 : 413-418
5. Avery TL, Rehg JE, Lumm WC, et al (1989) Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 49 : 4972-4978
6. Avramis VI Plunkett W (1982) Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42 : 2587-2591
7. Avramis VI, Champagne J, Sato J, et al (1990) Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 50 : 7226-7231
8. Bagnara AS, Hershfield MS ( 1982) Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells. Proc Nat Acad Sci USA 79 : 2673-2677
9. Barankiewicz J, Cohen A (1984) Evidence for distinct catabolic pathways of adenine ribonucleotides and deoxyribonucleotides in human T lymphoblastoid cells. J Biol Chem 259 : 15178-15181
10. Barrueco JR, Jacobsen DM, Chang C-H. et al (1987) Proposed mechanism of therapeutic selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 47 : 700-706
11. Bennett LL Jr, Chang C-H, Allan PW, et al (1985) Metabolism and metabolic effects of halopurine nucleosides in tumor cells in culture. Nucleosides Nucleotides 4 : 107-116
12. Beutler E, Piro LD, Saver A, et al (1991) 2-Chlorodeoxyadenosine (2CdA): A potent Chemotherapeutic and immunosuppressive nucleoside. Leuk Lymph 5 : 1-8
13. Brockman RW, Schabel FM Jr, Montgomery JA (1977) Biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem Pharmacol 26 : 2193-2196
14. Carson DA Wasson DB, Beutler E (1984) Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Nat Acad Sci USA 81 : 2232-2236
15. Carson DA, Wasson DB, Kaye J, et al (1980) Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Nat Acad Sci USA 77 : 6865-6869
16. Cass CE, Au-Yeung T (1976) Enhancement of 9-β-D-arabinofuranosyladenine toxicity to mouse leukemia L1210 in vitro by 2′-deoxycoformycin. Cancer Res 36 : 1508-1513
17. Catapano CV, Perrino FW, Fernandes DJ (1993) Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate. A mechanism for DNA synthesis inhibition. J Biol Chem 268 : 7179-7185
18. Christensen LF, Broom AD, Robins MJ, et al (1972) Synthesis and biological activity of selected 2,6,-disubstituted-(2-deoxy-α- and β-D-erythro-pentofuranosyl)purines. J Med Chem 15 : 735-739
19. Danhauser L, Plunkett W, Keating M, et al (1996) 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18 : 145-152
20. Dow LW, Bell DE, Poulakos L, et al (1980) Difference in metabolism and cytotoxicity between 9-β-D-arabinofuranosyladenine and 9-β-D-arabinofuranosyl-2-fiuoroadenine in human leukemic lymphoblasts. Cancer Res 40 : 1405-1410
21. Grever MR, Siaw MFE, Jacob WF, et al (1981) The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57 : 406-417
22. Griffig J, Koob R, Blakley RL (1989) Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastoid cells. Cancer Res 49 : 6923-6928
23. Harris BA, Plunkett W (1981) Biochemical basis for the cytotoxicity of 9-β-D-xylofuranosyladenine in Chinese hamster ovary cells. Cancer Res 41 : 1039-1044
24. Hentosh P, Koob R, Blakley RL (1990) Incorporation of 2-halogeno-2′deoxyadenosine 5′-triphosphates into DNA during replication by human DNA polymerases α and β. J Biol Chem 265 : 4033-4040
25. Hersh MR, Kuhn J, Philips JL, et al (1986) Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17 : 277-280
26. Hershfield MS, Fetter JE, Small MC, et al (1982) Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem 257 : 6380-6386
27. Hershfield, MS, Kredich NM, Ownby DR, et al (1979) In vivo inactivation of S-adenosyl homocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest 63 : 807-811
28. Huang M-C, Ashmun RA, Avery TL, et al (1986) Effects of cytotoxicity of 2-chloro-2′-deoxyadenosine and 2-bromo-2′-deoxyadenosine on cell growth, clonogenicity, DNA synthesis and cell cycle kinetics. Cancer Res 46 : 2363-2368
29. Huang M-C Hatfield K, Roetker AW, et al (1981) Effects of cytotoxicity of 2-chloro-2′-deoxyadenosine: facile enzymatic preparation and growth inhibitory effects on human cell lines. Biochem Pharmac 30 : 2663-2671
30. Huang P, Chubb S, Plunkett W (1990) Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265 : 16617-16625
31. Huang P, Plunkett W (1991) Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Molec Pharmac 39 : 449-455
32. Huang P, Siciliano MJ, Plunkett W (1989) Gene deletion, a mechanism of induced mutation by arabinofuranosyl-2-fluoroadenine. Mutat Res 210 : 291-301
33. Hutton JJ, Von Hoff DD, Kuhn J, et al (1984) Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44 : 4183-4186
34. Johns DG, Adamson RH (1979) Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin. Biochem Pharmac 25 : 1441-1444
35. Juliusson G, Heldal D, Hippe E, et al (1995) Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13 : 989-995
36. Kamiya K, Huang P, Plunkett W (1996) Inhibition of the 3′->5′ exonuclease of human DNA polymerase ε by fludarabine-terminated DNA. J Biol Chem 271 : 19428-19435
37. Kearns CM, Blakley RL, Santana VM, et al (1994) Pharmacokinetics of cladribine (2-Chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 54 : 1235-1239.
38. Kemena A, Fernandez M, Bauman J, et al (1991) A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta 200 : 95-106
39. Kemena A, Keating MJ, Plunkett W (1990) Plasma and cellular bioavailability of oral fludarabine. Blood 78 [Suppl 1] : 52a
40. Kemena A, O'Brien S, Kantarjian H, et al (1993) Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymph 10 : 187-193
41. Lasko DD, Tomkinson AE, Lindahl T (1990) Eukaryotic DNA ligases. Mutat Res 236 : 277-287
42. LePage GA, Khaliq A, Gottlieb JA (1973) Studies of 9-β-D-arabinofuranosyladenine in man. Drug Metab Dispos 1 : 756-759
43. LePage GA, Lin YT, Orth RE, Gottlieb JA (1972) 5′-Nucleotides as potential formulations for administering nucleoside analogs in man. Cancer Res 32 : 2441-2444
44. LePage GA, Worth LS, Kimball AP (1976) Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin. Cancer Res 36 : 1481-1485
45. Liliemark J, Albertioni F, Hassan M, et al (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routs of administration. J Clin Oncol 10 : 1514-1518
46. Liliemark J, Albertioni F, Edlund C, et al (1995) Bioavailability and bacterial degradation of rectally administered 2-chloro-2′-deoxyadenosine. J Pharm Biomed Anal 13 : 661-665
47. Liliemark J, Pettersson B, Juliusson G (1991) Determination of 2-chloro-2′-deoxyadenosine in human plasma. Biomedical Chromatogr 5 : 262-264
48. Liliemark JO, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 51 : 5570-5572
49. Major PP, Agarwal RP, Kufe DW (1981) Clinical pharmacology of deoxycoformycin. Blood 58 : 91-96
50. Malspeis L, Grever MR, Staubus AE, et al (1990) Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigations of fludarabine phosphate. Sem Oncol 17[Suppl 8] : 18-32
51. Malspeis L, Staubus AE, Lyon ME (1989) Oral bioavailability of 2-F-ara-A from fludarabine phosphate capsules in dogs. Proc Am Assn Cancer Res 30 : 534
52. Malspeis L, Weinrib AB, Strabus AE, et al (1994) Clinical pharmacokinetics of 2′-deoxycoformycin. Cancer Treat Symp 2 : 7-15
53. Montgomery JA, Hewson K (1960) Synthesis of potential anticancer agents. XX. 2-fluoropurines. J Am Chem Soc 82 : 463-468
54. Montgomery JA, Hewson K (1969) Nucleosides of 2-fluoroadenine. J Med Chem 12 : 498-504.
55. Nakamura H, Koyama G, Iitaka Y, et al (1974) Structure of coformycin, an unusual nucleoside of microbial origin. J Am Chem Soc 96 : 4327-4328
56. Parker WB, Bapat AR, Shen J-X, et al (1988) Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase and ribonucleotide reductase. Molec Pharmacol 34 : 485-491
57. Parker, W and Cheng, Y-C. (1987) Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Molec Pharmac 31 : 146-151
58. Piro LD, Carrera CJ, Carson DA, et al (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chloro-deoxyadenosine. N Engl J Med 322 : 1117-1121
59. Plunkett W (1985) Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues. N Y Acad Sci 451: 150-159
60. Plunkett W, Alexander L, Chubb S, et al (1980) Comparison of the toxidty and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40 : 2349-2355
61. Plunkett W, Benjamin RS, Keating MJ, et al (1982) Modulation of 9-β-D-arabinofuranosyiadenine 5′-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2′-deoxycoformycin during therapy with 9-β-D-arabinofuranosyladenine. Cancer Res 42 : 2092-2096
62. Plunkett W, Feun L, Benjamin RS, Keating MJ, Freireich EJ (1984) Modulation of vidarabine metabolism by 2′-deorycoformycin for therapy of acute leukemia. Cancer Treat Symp 2 : 23-28
63. Plunkett W, Huang P, Gandhi V (1990) Metabolism and action of fludarabine phosphate. Sem Oncol 17 [Suppl 8] : 3-17
64. Plunkett W, Saunders PP (1991) Metabolism and action of purine nucleoside analogs. Pharmac Ther 49 : 2339-268
65. Poplack DG, Sallan SE, Rivera G et al (1981) Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 41 : 3343-3346
66. Robertson LE, O'Brien S, Kantarjian H, et al (1995) A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9 : 1444-1449
67. Santana VM, Mirro JM Jr, Kearns C et al (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10 : 362-370
68. Saven A, Cheung WK, Smith I, et al (1996) Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 14 : 978-983
69. Simon LN, Bauer RJ, Tolman RL, et al (1970) Calf intestine adenosine deaminase. Substrate specificity. Biochemistry 9 : 573-577
70. Skipper HE, Montgomery JA, Thompson JR, et al (1959) Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms. Cancer Res 19 : 425-437
71. Spriggs D, Robbins G, Mitchell T, et al (1986) Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem Pharmac 35 : 247-252
72. Thelander L, Reichard P (1979) Reduction of ribonucleotides. Ann Rev Biochem 48 : 133-158
73. Tseng WC, Derse D, Cheng Y-C, et al (1982) In vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Molec Pharmac 21 : 474-477
74. White L, Shaddix SC, Brocckman RW, et al (1982) Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42 : 2260-2264
75. Wilson DK, Rudolph FB, Quiocho FA (1991) Atomic structure of adenosine deaminase complexed with transition-state analog: understanding catalysis and immunodeficiency mutations. Science 252 : 1278-1284
76. Woo PKW, Dion HW, Lange SM, et al (1974) A novel adenosine and ara-A deaminase inhibitor, (R)-3-(2-deoxy-β-D-erythropentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5][1, 3]-diazapin-8-ol. J Heterocyc Chem 11 : 641-643
77. Yang S-W, Huang P, Plunkett W, et al (1992) Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 267 : 2345-2349